{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:49:32Z","timestamp":1787870972050,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-02998-4","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:11:08Z","timestamp":1730193068000},"page":"4601-4616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type\u00a02 Comorbidities"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4439","authenticated-orcid":false,"given":"Mark","family":"Boguniewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Arkwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara Rodr\u00edguez","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"4","key":"2998_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"2998_CR2","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1525-1470.2010.01215.x","volume":"27","author":"HA Al Shobaili","year":"2010","unstructured":"Al Shobaili HA. The impact of childhood atopic dermatitis on the patients\u2019 family. Pediatr Dermatol. 2010;27(6):618\u201323. https:\/\/doi.org\/10.1111\/j.1525-1470.2010.01215.x.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2998_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.iac.2010.05.004","volume":"30","author":"SL Chamlin","year":"2010","unstructured":"Chamlin SL, Chren M-M. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281\u20138. https:\/\/doi.org\/10.1016\/j.iac.2010.05.004.","journal-title":"Immunol Allergy Clin North Am"},{"key":"2998_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19500","author":"K Eyerich","year":"2023","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19500.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2998_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.anai.2021.02.026","volume":"127","author":"MH Knudgaard","year":"2021","unstructured":"Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2021;127(1):49-56.e1. https:\/\/doi.org\/10.1016\/j.anai.2021.02.026.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2998_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","volume":"84","author":"N Ravnborg","year":"2021","unstructured":"Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(2):471\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.055.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2998_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaci.2015.10.049","volume":"137","author":"T Tsakok","year":"2016","unstructured":"Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.049.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2998_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jaad.2021.10.038","volume":"86","author":"AS Paller","year":"2022","unstructured":"Paller AS, Mina-Osorio P, Vekeman F, et al. Prevalence of type\u00a02 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence. J Am Acad Dermatol. 2022;86(4):758\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.038.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2998_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2998_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaci.2007.05.042","volume":"120","author":"AE Van der Hulst","year":"2007","unstructured":"Van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2998_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2007.06.041","volume":"7","author":"N Aberle","year":"2018","unstructured":"Aberle N, Kljai\u0107 Bukvi\u0107 B, Bleki\u0107 M, et al. Allergic diseases and atopy among schoolchildren in eastern Croatia. Acta Clin Croat. 2018;7(1):82\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.041.","journal-title":"Acta Clin Croat"},{"issue":"1","key":"2998_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2007.06.041","volume":"58","author":"R Kapoor","year":"2008","unstructured":"Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.041.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2998_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaip.2012.11.005","volume":"1","author":"MM Bergmann","year":"2013","unstructured":"Bergmann MM, Caubet JC, Boguniewicz M, Eigenmann PA. Evaluation of food allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(1):22\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2012.11.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2998_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1365-2222.2004.1953.x","volume":"34","author":"K Breuer","year":"2004","unstructured":"Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy. 2004;34(5):817\u201324. https:\/\/doi.org\/10.1111\/j.1365-2222.2004.1953.x.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"2998_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/s0022-3476(85)80390-5","volume":"107","author":"HA Sampson","year":"1985","unstructured":"Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr. 1985;107(5):669\u201375. https:\/\/doi.org\/10.1016\/s0022-3476(85)80390-5.","journal-title":"J Pediatr"},{"issue":"5","key":"2998_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"14","key":"2998_CR17","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2998_CR18","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2998_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type\u00a02 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"key":"2998_CR20","unstructured":"Regeneron Pharmaceuticals, Inc.\/sanofi-aventis U.S. LLC. Highlights of Prescribing Information. In: DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use. US Food and Drug Administration. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s040lbl.pdf. Accessed Nov 25, 2023."},{"issue":"2","key":"2998_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"issue":"10013","key":"2998_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase\u00a02b trial. Lancet. 2016;387(10013):40\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8.","journal-title":"Lancet"},{"issue":"24","key":"2998_CR23","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"10086","key":"2998_CR24","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"2998_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase\u00a0III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"10356","key":"2998_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6\u00a0months to younger than 6\u00a0years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"3","key":"2998_CR27","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","volume":"9","author":"M Boguniewicz","year":"2021","unstructured":"Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212-23.e6. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.059.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2998_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2998_CR29","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase\u00a03 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2998_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase\u00a0IIa open-label trial and subsequent phase\u00a0III open-label extension. Br J Dermatol. 2020;182(1):85\u201396. https:\/\/doi.org\/10.1111\/bjd.18476.","journal-title":"Br J Dermatol"},{"issue":"11","key":"2998_CR31","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/all.15792","volume":"78","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Bourdin A, Papi A, et al. Dupilumab sustains efficacy in patients with moderate-to-severe type\u00a02 asthma regardless of inhaled corticosteroids dose. Allergy. 2023;78(11):2921\u201332. https:\/\/doi.org\/10.1111\/all.15792.","journal-title":"Allergy"},{"issue":"10039","key":"2998_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase\u00a02b dose-ranging trial. Lancet. 2016;388(10039):31\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(16)30307-5.","journal-title":"Lancet"},{"issue":"4","key":"2998_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","volume":"44","author":"AT Peters","year":"2023","unstructured":"Peters AT, Wagenmann M, Bernstein JA, et al. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Allergy Asthma Proc. 2023;44(4):265\u201374. https:\/\/doi.org\/10.2500\/aap.2023.44.230015.","journal-title":"Allergy Asthma Proc"},{"issue":"10209","key":"2998_CR34","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase\u00a03 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"1","key":"2998_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","volume":"142","author":"SF Weinstein","year":"2018","unstructured":"Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. Allergy Clin Immunol. 2018;142(1):171-7.e1. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.051.","journal-title":"Allergy Clin Immunol"},{"issue":"1","key":"2998_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type\u00a02 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2998_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","volume":"151","author":"GP Geba","year":"2023","unstructured":"Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2998_CR38","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00735-0.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02998-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:12:52Z","timestamp":1731139972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02998-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02998-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Boguniewicz has been an investigator for Incyte, Regeneron Pharmaceuticals Inc., and Sanofi, and participated on advisory boards for AbbVie, Amgen, Dermavant, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi. Lawrence D. Sher is an advisory board member for Aimmune Therapeutics, Optinose, Regeneron Pharmaceuticals Inc., and Sanofi; reports speaker fees from Regeneron Pharmaceuticals Inc. and Sanofi; and clinical trials funding from Aimmune Therapeutics, Amgen, AstraZeneca, Circassia, DBV Technologies, Galderma, GSK, Lupin, Merck, Mylan, Novartis, Novo Nordisk, Optinose, Pearl, Pfizer, Pulmagen, Roxane, Sanofi, Spirometrix, Teva, Vectura, and Watson Pharmaceuticals. Amy S. Paller is an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, LEO Pharma and UCB; a consultant for Amryt Pharma, Azitra, BioCryst, BMS, Boehringer Ingelheim, Castle Creek Biosciences, Eli Lilly, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Seanergy, TWi Biotechnology, and UCB; and a member of the data and safety monitoring board for AbbVie, Abeona Therapeutics, Catawba Research, Galderma, and InMed Pharmaceuticals. Peter D. Arkwright has acted as an investigator for Regeneron Pharmaceuticals Inc., and has received grants from and acted as an advisor for Sanofi. Shigemi Yoshihara has acted as an investigator for Regeneron Pharmaceuticals Inc., and has received grants from and acted as an advisor for Sanofi. Zhen Chen and Parul Shah are employees and shareholders of Regeneron Pharmaceuticals Inc. Ainara Rodr\u00edguez Marco is an employee of and may hold stock and\/or stock options in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The LIBERTY AD PRESCHOOL part\u00a0B study was conducted in accordance with the provisions of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. The study protocol was reviewed and approved by institutional review boards\/ethics committees. For each patient, written informed consent was obtained from a parent or legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}